進行膵臓癌に対するヒト白血球抗原A*2402制限腫瘍血管特異的ペプチドワクチン接種

基本情報

NCT ID: NCT00683358
ステータス: 不明
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 14
治験依頼者名: Tokyo University

概要

Feasibility and efficacy of combined modality intervention using chemotherapeutic agent gemcitabine with anti-angiogenic peptide vaccination targeting VRGFR1 should be determined in case of advanced/inoperable or therapy-resistant pancreatic cancer patients. Gemcitabine 1,000mg/m2 BSA will be administered on day1, day8, day15, day29, day36, day43, respectively. HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084; SYGVLLWEI) emulsified with Montanide ISA51 will be subcutaneously injected twice weekly for 8weeks (total 16 doses).

対象疾患

Pancreatic CancerPancreas Neoplasms

介入

VEGFR1-A24-1084 (SYGVLLWEI)(BIOLOGICAL)

依頼者（Sponsor）

Tokyo University(OTHER)

Human Genome Center, Institute Of Medical Science, University Of Tokyo(OTHER)

実施施設 (1)

一般社団法人　ＩＣＲ　附属　クリニカルリサーチ東京病院

Minato-ku, Tokyo, Japan